AlphaStocks
4.5
Weak

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)

Health Care / Life Sciences Tools & Services

S&P 500

$175.16

Below average on several measures. Research carefully.

Weak

Score based on 4 of 5 models — moderate confidence

#704out of 1127 in Health Care

Is CHARLES RIVER LABORATORIES INTERNATIONAL, INC. a Good Investment in 2026?

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) scores 4.5 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates CHARLES RIVER LABORATORIES INTERNATIONAL, INC. as Attractive (5/9). However, the Graham model rates it Caution. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. currently trades above its estimated fair value of $114, suggesting limited upside at current prices. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. ranks #704 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-4.4Market Cap9B

Estimated Fair Value

$113.8454% above

Trading above estimated fair value — the market may be pricing in future growth.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

Price vs intrinsic value

Lynch

Attractive

Growth rate vs price (PEG)

Greenblatt

Neutral

Top half (rank 48%)

Frequently Asked Questions

Is CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) a good investment?
Based on AlphaStocks' composite analysis, CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) scores 4.5 out of 10, earning a Weak rating. This score is below average, suggesting caution. Trading above estimated fair value — the market may be pricing in future growth.
What is CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s Piotroski F-Score?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is CRL overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $114, CRL appears overvalued. The stock currently trades 54% above its estimated fair value. Trading above estimated fair value — the market may be pricing in future growth.
How does CRL compare to other Health Care stocks?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. ranks #704 out of 1127 stocks in the Health Care sector, placing it in the top 62% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about CRL?
AlphaStocks evaluates CRL using five proven investment models. Piotroski: Attractive; Buffett: Neutral; Graham: Caution; Lynch: Attractive; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 4.5/10.

Similar Stocks

PARRFTIAZN

Compare CRL with

CRL vs PARRCRL vs FTICRL vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer